Public Reporting

This measure assesses the proportion of all newborn infants who did not complete a hearing screen prior to discharge, who went on to receive an outpatient screen before the child was 31 days of age.

*Numbering within the parentheses references the US national extension quality measure identifiers developed for the Use Cases published in the Integrating the Healthcare Enterprise (IHE) Quality, Research and Public Health (QRPH) EHDI Technical Framework Supplement available at www.ihe.net/Technical_Framework/index.cfm#quality

The proportion of acute MI patients >= 18 years of age that receive "perfect care" based upon their eligibility for each performance measures

Percentage of patients, regardless of age, with a current diagnosis of Stage 0 through IIC melanoma or a history of melanoma of any stage, without signs or symptoms suggesting systemic spread, seen for an office visit during the one-year measurement period, for whom no diagnostic imaging studies were ordered

The quarterly incidence rate of falls amongst PACE participants per 1,000 participant days.

The quarterly incidence rate of falls with injury amongst PACE participants per 1,000 participant days.

Prevalence of PACE-acquired pressure ulcers/injuries (Stages 3, 4, unstageable, and deep tissue injury) among PACE participants in a quarter, expressed as persons with 1 or more pressure ulcers/injuries divided by the number of participants on the PACE organization’s census who resided in a home setting (home or assisted living facility)for at least one day during the quarter.

Percentage of home health episodes of care in which the patient was assessed for pain, using a standardized pain assessment tool, at start/resumption of care.

Percentage of short term home health episodes of care during which pain interventions were included in the physician-ordered plan of care and implemented.

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who started antiviral treatment within the 12 month reporting period for whom quantitative hepatitis C virus (HCV) ribonucleic acid (RNA) testing was performed within 12 months prior to initiation of antiviral treatment

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who started antiviral treatment within the 12 month reporting period for whom hepatitis C virus (HCV) genotype testing was performed within 12 months prior to initiation of antiviral treatment